Calithera Biosciences, Inc.
343 Oyster Point Blvd
South San Francisco
137 articles with Calithera Biosciences, Inc.
New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab
Responses observed in patients with microsatellite stable (MSS) colorectal cancer, a disease not historically sensitive to checkpoint inhibition
Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma
Data shared in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that new data from two oncology programs have been selected for oral presentations at the European Society for Medical Oncology (ESMO) 2019 Congress to be held September 27-October 1, in Barcelona, Spain.
Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.
6/24/2019Plenty of biopharma companies released results from clinical trials last week. Here’s a look at the top stories.
Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma
Calithera Biosciences, Inc. announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat in combination with everolimus in patients with advanced renal cell carcinoma.
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839
Phase 1/2 trials expected to initiate 1Q2019
Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board.
Updated Results From Calithera Biosciences' Phase I Study of CB-839 in Combination With Paclitaxel in Patients With Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium
Based on these data, Calithera has opened a Phase 2 trial exploring the treatment combination in both first line and late line metastatic TNBC patients.
In an overall good year for pharma and biotech sectors, there have been some standouts.
Calithera Biosciences' Initial Results From Phase II Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting
CB-839 is an orally bioavailable glutaminase inhibitor currently in Phase 2 trials, and Opdivo® is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.
Calithera will webcast clinical update on CB-839 on November 11, 2017.
Calithera Announces First Patient Treated in Phase I Cohort of INCB01158 Dosed in Combination With Keytruda
The Phase 1 trial is designed to evaluate the safety and recommended Phase 2 dose of INCB01158 as a monotherapy, and in combination with immune checkpoint therapy.
Calithera Biosciences Initiates A Randomized Phase II Combination Trial Of CB-839 In Patients With Renal Cell Carcinoma
Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma
Calithera Biosciences Release: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented At The ASCO Annual Meeting